The biological basis of schizophrenia: New directions

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 22-27

  Weinberger, Daniel R ^a,b  

^a St Elizabeths Hospital   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; NEUROTRANSMITTER;

ARTICLE; BRAIN DEVELOPMENT; ENTORHINAL CORTEX; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ASPARTIC ACID; BRAIN; CHOLECYSTOKININ; DISEASE MODELS, ANIMAL; DOPAMINE; ENTORHINAL CORTEX; GAMMA-AMINOBUTYRIC ACID; GENETIC MARKERS; GLUTAMIC ACID; HUMANS; LINKAGE (GENETICS); RNA, MESSENGER; RODENTIA; SCHIZOPHRENIA;

EID: 0030761815     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gill M, Vallada H, Collier D, et al. A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:40-45
2. Moises HW, Yang L, Kristbjarnarson H, et al. An international two-stage genome-wide search for schizophrenia susceptibility genes [letter]. Nat Genet 1995;11:321-324
3. Pulver AE, Lasseter VK, Kasch L, et al. Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet (Neuropsychiatric Genetics) 1995;60:252-260
4. Rubinsztein DC, Leggo J, Crow TJ, et al. Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:495-498
5. Silverman JM, Greenberg DA, Altstiel LD, et al. Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. Am J Med Genet (Neuropsychiatric Genetics) 1996;67: 162-171
6. St. Clair D. Expanded CAG trinucleotide repeat of Huntington's disease gene in a patient with schizophrenia and normal striatal histology [letter]. J Med Genet 1994;31:658-659
7. Straub RE, MacLean CJ, O'Neill FA, et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet 1995;11:287-293
8. Baron M. Linkage results in schizophrenia [editorial]. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:121-123
9. Kalsi G, Brynjolfsson J, Butler R, et al. Linkage analysis of chromosome 22q12-13 in a United Kingdom/Icelandic sample of 23 multiplex schizophrenia families. Am J Med Genet (Neuropsychiatric Genetics) 1995;60: 298-301
10. Inayama Y, Yoneda H, Sakai T, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:103-105
11. Williams J, Spurlock G, McGuffin P, et al, and the European Multicentre Association Study of Schizophrenia (EMASS) Group. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 1996;347:1294-1296
12. Griffon N, Crocq MA, Pilon C, et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:63-70
13. Jonsson E, Lannfelt L, Sokoloff P, et al. Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr Scand 1993;87:345-349
14. Jain S, Leggo J, DeLisi LE, et al. Analysis of thirteen trinucleotide repeat loci as candidate genes for schizophrenia and bipolar affective disorder. Am J Med Genet (Neuropsychiatric Genetics) 1996;67:139-146
15. Grove WM, Clementz BA, Iacono WG, et al. Smooth pursuit ocular motor dysfunction in schizophrenia: evidence for a major gene. Am J Psychiatry 1992;149:1362-1368
16. Jones P, Rodgers B, Murray R, et al. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994;344: 1398-1402
17. Waldo M, Myles-Worsley M, Madison A, et al. Sensory gating deficits in parents of schizophrenics. Am J Med Genet (Neuropsychiatric Genetics) 1995;60:506-511
18. Akbarian S, Sucher NJ, Bradley D. et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30
19. Arnold SE, Hyman BT, van Hoesen GW, et al. Some cytoarchitectural abnormalities in the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991;48:625-633
20. Bertolino A, Nawroz S, Mattay V, et al. A regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 1996;153: 1554-1563
21. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65:303-326
22. Olney JE, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007
23. Tsai G, Passani L, Slusher B, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52: 829-836
24. Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995;16:87-110
25. Taber MT, Baker GB, Fibiger HC. Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo. Synapse 1996;24:165-172
26. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
27. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990;39:25-32
28. Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci 1994;55:1683-1699
29. Wolf SS, Hyde TM, Saunders RC, et al. Autobiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J Neural Transm Gen Sect 1995;102:55-65
30. Bacchus SE, Hyde TM, Herman MM, et al. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J Psychiatr Res. In press
31. Virgo L, Humphries C, Mortimer A, et al. Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry 1995;37:694-701
32. Yurgelun-Todd DA, Renshaw PF, Gruber SA, et al. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res 1996;19:55-59
33. Jaskiw GE, Juliano DM, Goldberg TE, et al. Cerebral ventricular enlargement in schizophreniform disorder does not progress: a seven year follow-up study. Schizophr Res 1994;14:23-28
34. Andreasen NC, Flashman L, Flaum M, et al. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA 1994; 272:1763-1769
35. Hyde TM, Nawroz S, Goldberg TE, et al. Is there cognitive decline in schizophrenia? a cross-sectional study. Br J Psychiatry 1994;164:494-500
36. Benes FM, Vincent SL, Alsterberg G, et al. Increased GABA-A binding in the superficial layers of cingulate cortex in schizophrenia. J Neurosci 1992; 12:924-929
37. Benes FM, Kahn Y, Vincent SL, et al. Differences in the subregional and cellular-distribution of GABA-A receptor-binding in the hippocampal-formation of schizophrenic brain. Synapse 1996;22:338-349
38. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346:552-557
39. Done DJ, Crow TJ, Johnstone EC, et al. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 1994; 309:699-703
40. Breslin NA, Weinberger DR. Neurodevelopmental implications of findings from brain imaging studies of schizophrenia. In: Mednick SA, Cannon TD, Barr CE, et al, eds. Fetal Neural Development and Adult Schizophrenia. New York, NY: Cambridge University Press; 1991:199-215
41. Zigun J, Weinberger DR. In vivo studies of brain morphology in patients with schizophrenia. In: Lindenmeyer JP, Kay SR, eds. New Biological Vistas on Schizophrenia. New York, NY: Brunner/Mazel; 1992:57-81
42. Akbarian S, Bunney WE Jr, Potkin SG, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-177
43. Akbarian S, Vinuela A, Kim JJ, et al. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187
44. Akbarian S, Kim JJ, Potkin SG, et al. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996;53:425-436
45. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993;9:67-75
46. Lipska BK, Weinberger DR. Behavioral effects of subchronic treatment with haloperidol or clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 1994;10:199-205
47. Lipska BK, Weinberger DR. Gonadectomy does not prevent novelty or drug-induced motor hyperresponsiveness in rats with neonatal hippocampal damage. Dev Brain Res 1994;78:253-258